BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 9300578)

  • 1. Effects of olomoucine, a selective inhibitor of cyclin-dependent kinases, on cell cycle progression in human cancer cell lines.
    Buquet-Fagot C; Lallemand F; Montagne MN; Mester J
    Anticancer Drugs; 1997 Jul; 8(6):623-31. PubMed ID: 9300578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases.
    Abraham RT; Acquarone M; Andersen A; Asensi A; Bellé R; Berger F; Bergounioux C; Brunn G; Buquet-Fagot C; Fagot D
    Biol Cell; 1995; 83(2-3):105-20. PubMed ID: 7549905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity.
    Alessi F; Quarta S; Savio M; Riva F; Rossi L; Stivala LA; Scovassi AI; Meijer L; Prosperi E
    Exp Cell Res; 1998 Nov; 245(1):8-18. PubMed ID: 9828096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclin-dependent kinase inhibitors block proliferation of human gastric cancer cells.
    Iseki H; Ko TC; Xue XY; Seapan A; Hellmich MR; Townsend CM
    Surgery; 1997 Aug; 122(2):187-94; discussion 194-5. PubMed ID: 9288122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ERK pathway mediates the activation of Cdk2 in IGF-1-induced proliferation of human osteosarcoma MG-63 cells.
    Zhang W; Lee JC; Kumar S; Gowen M
    J Bone Miner Res; 1999 Apr; 14(4):528-35. PubMed ID: 10234573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of the cyclin-dependent kinase inhibitor olomoucine on cell cycle kinetics.
    Schutte B; Nieland L; van Engeland M; Henfling ME; Meijer L; Ramaekers FC
    Exp Cell Res; 1997 Oct; 236(1):4-15. PubMed ID: 9344580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and in vitro evaluation of novel 2,6,9-trisubstituted purines acting as cyclin-dependent kinase inhibitors.
    Legraverend M; Ludwig O; Bisagni E; Leclerc S; Meijer L; Giocanti N; Sadri R; Favaudon V
    Bioorg Med Chem; 1999 Jul; 7(7):1281-93. PubMed ID: 10465404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.
    Meijer L; Borgne A; Mulner O; Chong JP; Blow JJ; Inagaki N; Inagaki M; Delcros JG; Moulinoux JP
    Eur J Biochem; 1997 Jan; 243(1-2):527-36. PubMed ID: 9030781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel strategy for inhibiting growth of human pancreatic cancer cells by blocking cyclin-dependent kinase activity.
    Iseki H; Ko TC; Xue XY; Seapan A; Townsend CM
    J Gastrointest Surg; 1998; 2(1):36-43. PubMed ID: 9841966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular effects of olomoucine in human lymphoma cells differing in p53 function.
    Fan S; Duba DE; O'Connor PM
    Chemotherapy; 1999; 45(6):437-45. PubMed ID: 10567774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adenovirus-mediated E2F-1 gene transfer induces an apoptotic response in human gastric carcinoma cells that is enhanced by cyclin dependent kinase inhibitors.
    Atienza C; Elliott MJ; Dong YB; Yang HL; Stilwell A; Liu TJ; McMasters KM
    Int J Mol Med; 2000 Jul; 6(1):55-63. PubMed ID: 10851267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olomoucine, an inhibitor of the cdc2/cdk2 kinases activity, blocks plant cells at the G1 to S and G2 to M cell cycle transitions.
    Glab N; Labidi B; Qin LX; Trehin C; Bergounioux C; Meijer L
    FEBS Lett; 1994 Oct; 353(2):207-11. PubMed ID: 7523194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Caspase-mediated Cdk2 activation is a critical step to execute transforming growth factor-beta1-induced apoptosis in human gastric cancer cells.
    Kim SG; Kim SN; Jong HS; Kim NK; Hong SH; Kim SJ; Bang YJ
    Oncogene; 2001 Mar; 20(10):1254-65. PubMed ID: 11313870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early inhibition of DNA synthesis in the developing rat cerebral cortex by the purine analogues olomoucine and roscovitine.
    Yakisich JS; Sidén A; Idoyaga Vargas V; Eneroth P; Cruz M
    Biochem Biophys Res Commun; 1998 Feb; 243(3):674-7. PubMed ID: 9500988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Helicobacter pylori releases a factor(s) inhibiting cell cycle progression of human gastric cell lines by affecting cyclin E/cdk2 kinase activity and Rb protein phosphorylation through enhanced p27(KIP1) protein expression.
    Sommi P; Savio M; Stivala LA; Scotti C; Mignosi P; Prosperi E; Vannini V; Solcia E
    Exp Cell Res; 2002 Nov; 281(1):128-39. PubMed ID: 12441136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cyclin-dependent kinase inhibitor, butyrolactone I, inhibits phosphorylation of RB protein and cell cycle progression.
    Kitagawa M; Higashi H; Takahashi IS; Okabe T; Ogino H; Taya Y; Hishimura S; Okuyama A
    Oncogene; 1994 Sep; 9(9):2549-57. PubMed ID: 8058318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells.
    David-Pfeuty T
    Oncogene; 1999 Dec; 18(52):7409-22. PubMed ID: 10602500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiproliferative effect of plant cytokinin analogues with an inhibitory activity on cyclin-dependent kinases.
    Vermeulen K; Strnad M; Krystof V; Havlícek L; Van der Aa A; Lenjou M; Nijs G; Rodrigus I; Stockman B; van Onckelen H; Van Bockstaele DR; Berneman ZN
    Leukemia; 2002 Mar; 16(3):299-305. PubMed ID: 11896531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclin E-cdk2 activation is associated with cell cycle arrest and inhibition of DNA replication induced by the thymidylate synthase inhibitor Tomudex.
    Yin MB; Guo B; Panadero A; Frank C; Wrzosek C; Slocum HK; Rustum YM
    Exp Cell Res; 1999 Feb; 247(1):189-99. PubMed ID: 10047461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202.
    Raynaud FI; Whittaker SR; Fischer PM; McClue S; Walton MI; Barrie SE; Garrett MD; Rogers P; Clarke SJ; Kelland LR; Valenti M; Brunton L; Eccles S; Lane DP; Workman P
    Clin Cancer Res; 2005 Jul; 11(13):4875-87. PubMed ID: 16000586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.